Active filters
Target Symbol
- TNF
Reactivities
- Human
Filter by
Category
Antibody Hosts
Clonalities
Conjugates
Modifications
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (2)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- Unmodified (1)
Assay Types
Assay Platforms
Pathways
- Adipocytokine signaling pathway (53)
- Allograft rejection (53)
- Alzheimer's disease (53)
- Amyotrophic lateral sclerosis (ALS) (53)
- Apoptosis (53)
- Asthma (53)
- Cytokine-cytokine receptor interaction (53)
- Dilated cardiomyopathy (53)
- Fc epsilon RI signaling pathway (53)
- Graft-versus-host disease (53)
- Hematopoietic cell lineage (53)
- Hypertrophic cardiomyopathy (HCM) (53)
- MAPK signaling pathway (53)
- NOD-like receptor signaling pathway (53)
- Natural killer cell mediated cytotoxicity (53)
- RIG-I-like receptor signaling pathway (53)
- Systemic lupus erythematosus (53)
- T cell receptor signaling pathway (53)
- TGF-beta signaling pathway (53)
- Toll-like receptor signaling pathway (53)
- Type I diabetes mellitus (53)
- Type II diabetes mellitus (53)